Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial HypertensionJune 2, 2016 | Press Release
Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque PsoriasisMay 16, 2016 | Press Release
Galectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced FibrosisMay 11, 2016 | Press Release
Galectin Therapeutics, Inc.
Stock price updates every 30 minutes.